Leerink Partnrs Weighs in on IPSC FY2029 Earnings

Century Therapeutics, Inc. (NASDAQ:IPSC - Free Report) - Stock analysts at Leerink Partnrs issued their FY2029 earnings estimates for shares of Century Therapeutics in a research report issued to clients and investors on Thursday, February 13th. Leerink Partnrs analyst D. Graybosch anticipates that the company will earn ($1.18) per share for the year. The consensus estimate for Century Therapeutics' current full-year earnings is ($1.63) per share.

Several other analysts also recently issued reports on the stock. HC Wainwright reaffirmed a "buy" rating and set a $5.00 price objective on shares of Century Therapeutics in a report on Wednesday, January 22nd. Piper Sandler cut their target price on shares of Century Therapeutics from $12.00 to $4.00 and set an "overweight" rating for the company in a research note on Monday, December 30th. Guggenheim reiterated a "buy" rating on shares of Century Therapeutics in a research note on Wednesday, January 22nd. Finally, Chardan Capital cut their target price on shares of Century Therapeutics from $17.00 to $11.00 and set a "buy" rating for the company in a research note on Thursday, November 7th. Six equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company presently has a consensus rating of "Buy" and a consensus target price of $10.00.

Century Therapeutics Price Performance

Shares of NASDAQ IPSC traded down $0.01 during trading hours on Friday, hitting $0.77. 480,850 shares of the stock were exchanged, compared to its average volume of 492,811. The company's 50 day moving average is $0.95 and its 200 day moving average is $1.33. The firm has a market capitalization of $65.32 million, a P/E ratio of -0.42 and a beta of 1.73. Century Therapeutics has a one year low of $0.68 and a one year high of $5.51.

Hedge Funds Weigh In On Century Therapeutics

Large investors have recently bought and sold shares of the stock. SG Americas Securities LLC acquired a new position in shares of Century Therapeutics in the 3rd quarter valued at $27,000. Geode Capital Management LLC raised its stake in shares of Century Therapeutics by 2.4% in the 4th quarter. Geode Capital Management LLC now owns 991,595 shares of the company's stock valued at $1,002,000 after buying an additional 23,413 shares in the last quarter. Jane Street Group LLC raised its stake in shares of Century Therapeutics by 166.2% in the 4th quarter. Jane Street Group LLC now owns 48,036 shares of the company's stock valued at $49,000 after buying an additional 29,992 shares in the last quarter. Bank of America Corp DE raised its stake in shares of Century Therapeutics by 109.1% in the 4th quarter. Bank of America Corp DE now owns 66,043 shares of the company's stock valued at $67,000 after buying an additional 34,466 shares in the last quarter. Finally, Marshall Wace LLP acquired a new position in shares of Century Therapeutics in the 4th quarter valued at $36,000. 50.20% of the stock is currently owned by institutional investors and hedge funds.

Century Therapeutics Company Profile

Century Therapeutics, Inc, a biotechnology company, engages in the development of genetically engineered allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. Its lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy, under Phase 1 trials targeting CD19 for relapsed, refractory B-cell lymphoma.